Changchun BCHT Biotechnology Co.SSE: 688276

Report for Q3 2024

Oct 26, 2024 · Issued by Changchun BCHT Biotechnology Co. via Shanghai Stock Exchange

Filed with SSE · Oct 26, 2024

On 6ix: 6ix.com/news/report-for-q3-2024-294

Report for Q3 2024

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:
View Attachment

6ix hasn’t read this filing yet.

Changchun BCHT Biotechnology Co. on 6ix

Earlier from Changchun BCHT Biotechnology

Announcement on Convening Performance Briefing for Q3 2024Oct 19, 2024
Announcement on the Judicial Freezing of Partial Shares Held by Shareholders with over 5% ShareholdingOct 9, 2024
Announcement on Shareholding Reduction Plan through Call Auction by Shareholders Holding Over 5% of SharesSep 14, 2024
Announcement on Returning Raised Funds Previously Used to Temporarily Supplement Current Capital and Using Some Idle Raised Funds to Temporarily Supplement Current CapitalAug 16, 2024
Announcement on Convening Semi-annual Performance Briefing 2024Aug 9, 2024

Later from Changchun BCHT Biotechnology

Indicative Announcement on Change in Equity of Shareholders with Over 5% Shares to 5%Nov 7, 2024
Announcement on Electing Employee Representative Supervisor of the 6th Board of SupervisorsNov 23, 2024
Announcement on Completing Term Change and Election of the Board of Directors and the Board of Supervisors and Appointing Senior Management Members and Securities Affairs RepresentativeDec 11, 2024
Announcement on Voluntary Disclosure of Approval for Clinical Trial Application of Type II Herpes Simplex Virus mRNA VaccineDec 21, 2024
Announcement on the Approval of Voluntary Disclosure of Clinical Trial Application for Freeze-dried Haemophilus Influenzae Type b Conjugate VaccineDec 26, 2024

All Changchun BCHT Biotechnology news releases

Follow Changchun BCHT Biotechnology into a list and get an email when it puts out news.

Follow Changchun BCHT Biotechnology